Researchers found that a new clinical trial, called LUNA-2, is testing a combination of immunotherapy and fecal microbiota transplantation (FMT) to improve treatment outcomes for lung cancer patients. This innovative approach aims to enhance the effectiveness of existing treatments, potentially offering new hope for individuals whose lung cancer is not responding to standard therapies. Lung cancer is a major health concern, with only about 27% of patients surviving beyond five years after diagnosis. If successful, this trial could help many people live longer and experience fewer side effects from their treatments.

The LUNA-2 trial is particularly important because it targets non-small cell lung cancer, the most common type of lung cancer in Canada. By enrolling 160 participants, this study aims to explore how FMT can boost the immune system’s response to treatment. Past studies in other cancers have shown that FMT can improve treatment success and reduce adverse effects. This trial is a significant step forward in cancer research, as it is the largest of its kind in Canada and could lead to new strategies for managing lung cancer.

Currently, the LUNA-2 trial is in the clinical stage, meaning it involves real patients and aims to gather concrete evidence about the effectiveness of this treatment combination. While the results are not yet available, the trial is built on promising findings from earlier studies. It represents a collaborative effort between the Canadian Cancer Society and the Weston Family Foundation, highlighting the importance of funding and research partnerships in the fight against cancer.

Source: globenewswire.com